Novartis AG ADR (NVS)vsProMIS Neurosciences Inc. (PMN)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
PMN
ProMIS Neurosciences Inc.
$9.13
-6.17%
HEALTHCARE · Cap: $91.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 748386130% more annual revenue ($56.58B vs $7,560). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PMN
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for PMN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PMN
The strongest argument for PMN centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PMN
The primary concerns for PMN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while PMN is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PMN is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →ProMIS Neurosciences Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
ProMIS Neurosciences Inc. is an innovative biotechnology firm dedicated to developing groundbreaking therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the company excels in identifying and targeting misfolded proteins linked to these conditions, positioning its drug candidates to offer enhanced safety and efficacy. With a robust pipeline at various stages of development, ProMIS is strategically positioned to advance critical neurotherapeutic options that address significant unmet medical needs in the biopharmaceutical landscape, making it an appealing prospect for institutional investors seeking growth in the healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?